FDA Says New Life Pharma Semaglutide and Tirzepatide Multi-Dose Vials Are Unapproved New Drugs
On April 14, 2026, FDA issued a warning letter to New Life Pharma LLC (Northvale, NJ) after a February 2026 inspection. FDA says the firm’s "Semaglutide Sterile Multi-Dose Vial" and "Tirzepatide Sterile Multi-Dose Vial" products are "unapproved new drugs" and misbranded, and cites CGMP and registration-and-listing violations under the FD&C Act.
What this meansGLP-1 vials sold outside the approved supply chain — and outside legitimate pharmacy compounding — are unapproved drugs; verifying that a product traces back to a licensed pharmacy is one of the most basic checks a patient can make.
Source: FDA original ↗